Zasositinib (TAK-279) achieved primary endpoints in a Phase 3 clinical trial targeting patients with moderate to severe plaque psoriasis, with over half achieving PASI90 and approximately 30% achieving PASI100 at week 16.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u26055","jir_publication_date":"2025-12-18","jir_source_link":"[Placeholder]","jir_short_summary":"Zasositinib (TAK-279) achieved primary endpoints in a Phase 3 clinical trial targeting patients with moderate to severe plaque psoriasis, with over half achieving PASI90 and approximately 30% achieving PASI100 at week 16.","jir_summary":"### Overview of the Product\/Service\nZasositinib (TAK-279) is a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor for plaque psoriasis. In two pivotal Phase 3, randomized, multicenter, double-blind, placebo- and active-controlled clinical trials (LATITUDE Psoriasis Phase 3 trials) involving adult patients with moderate to severe disease, the primary efficacy endpoints at week 16 \u2014 Physician's Global Assessment (sPGA) 0\/1 and PASI75 \u2014 were met. All 44 secondary endpoints, including PASI90 and PASI100, were also achieved. The drug demonstrated generally good tolerability, with a safety profile consistent with previous clinical trials. New drug applications are planned to be submitted to the FDA and other regulatory authorities in fiscal year 2026.\n\n### Market Impact and Outlook\nZasositinib has the potential to become a leading oral treatment option for plaque psoriasis patients by providing complete clearance of skin lesions with once-daily oral dosing, combining safety, high efficacy, and rapid onset of action. Ongoing clinical trials include head-to-head studies against competitor deucravacitinib, as well as trials in indications such as psoriatic arthritis, Crohn's disease, and ulcerative colitis, which are expected to drive significant future revenue contributions. This positions Zasositinib as a strategic product strengthening Takeda's pipeline and redefining medical care.","jir_financial_highlights":"PASI90 Achievement Rate at Week 16: Over half (Increasing trend (from week 4 to week 24))\nPASI100 Achievement Rate at Week 16: Approximately 30% (Increasing trend (from week 4 to week 24))\nSafety Profile: Generally favorable (No new safety signals)","jir_category":"Strategy\/Investment,Other","jir_hashtags":"#TakedaPharmaceuticalCompanyLimited,#Zasositinib,#NewProduct,#JapaneseStocks","jir_key_figures":"Product\/Service Name: Zasositinib (TAK-279)\nLaunch\/Start Date: Fiscal year 2026 onwards (new drug application planned)\nTarget Market: Plaque psoriasis market and immune-mediated inflammatory disease area\nDevelopment Stage: Phase 3 clinical trials completed, approval application preparation underway","jir_meta_title":"Takeda Pharmaceutical\u2019s Zasositinib Shows Breakthrough Efficacy in Phase 3 Trial for Plaque Psoriasis","jir_meta_description":"Takeda Pharmaceutical Company Limited announced Phase 3 clinical trial results of Zasositinib (TAK-279), demonstrating improvement of skin lesions with once-daily oral dosing in patients with moderate to severe plaque psoriasis.","jir_og_title":"Takeda Pharmaceutical Opens New Era in Plaque Psoriasis Treatment with Zasositinib Phase 3 Clinical Trial","jir_og_description":"Zasositinib (TAK-279) showed over half achieving PASI90 and approximately 30% achieving PASI100 at week 16, with a favorable safety profile. Approval applications are planned from fiscal year 2026.","jir_og_image_url":"\/assets\/og\/company-product-announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-7322","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n